Click here to get full coverage on Does Replimune Group (REPL) have the potential to rally 79.61% as Wall Street analysts expect? - MSN

Does Replimune Group (REPL) have the potential to rally 79.61% as Wall Street analysts expect?  MSN

Does Replimune Group (REPL) have the potential to rally 79.61% as Wall Street analysts expect? - MSN

Click here to get full coverage on Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat

Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL  MarketBeat

Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat

Click here to get full coverage on Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman  PR Newswire

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

Click here to get full coverage on Replimune at Leerink, Jefferies investor events March 9–10 - Stock Titan

Replimune at Leerink, Jefferies investor events March 9–10  Stock Titan

Replimune at Leerink, Jefferies investor events March 9–10 - Stock Titan

Click here to get full coverage on Replimune Stock Pre-Market (+16%): Sector Momentum Lifts Oncolytic Virus Peers - Trefis

Replimune Stock Pre-Market (+16%): Sector Momentum Lifts Oncolytic Virus Peers  Trefis

Replimune Stock Pre-Market (+16%): Sector Momentum Lifts Oncolytic Virus Peers - Trefis

Click here to get full coverage on REPL: Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress - TradingView

REPL: Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress  TradingView

REPL: Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress - TradingView

Click here to get full coverage on BMO Capital Maintains Replimune(REPL.US) With Hold Rating, Maintains Target Price $11 - 富途牛牛

BMO Capital Maintains Replimune(REPL.US) With Hold Rating, Maintains Target Price $11  富途牛牛

BMO Capital Maintains Replimune(REPL.US) With Hold Rating, Maintains Target Price $11 - 富途牛牛

Click here to get full coverage on $REPL stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is down 8% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - Zacks Investment Research

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug  Zacks Investment Research

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - Zacks Investment Research

Click here to get full coverage on Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL - MarketBeat

Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL  MarketBeat

Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL - MarketBeat

Click here to get full coverage on A Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial Results - Yahoo Finance

A Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial Results  Yahoo Finance

A Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial Results - Yahoo Finance

Click here to get full coverage on $REPL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma - Stock Titan

PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma  Stock Titan

PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma - Stock Titan

Click here to get full coverage on Boxer Capital Management LLC Has $4.40 Million Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat

Boxer Capital Management LLC Has $4.40 Million Stock Holdings in Replimune Group, Inc. $REPL  MarketBeat

Boxer Capital Management LLC Has $4.40 Million Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat

Click here to get full coverage on Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Yahoo Finance

Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’  Yahoo Finance

Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Yahoo Finance

Click here to get full coverage on Quinn Opportunity Partners LLC Invests $2.73 Million in Replimune Group, Inc. $REPL - MarketBeat

Quinn Opportunity Partners LLC Invests $2.73 Million in Replimune Group, Inc. $REPL  MarketBeat

Quinn Opportunity Partners LLC Invests $2.73 Million in Replimune Group, Inc. $REPL - MarketBeat

Click here to get full coverage on Replimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed? - Yahoo Finance

Replimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed?  Yahoo Finance

Replimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Replimune Group (NASDAQ:REPL) Trading 11.1% Higher - Here's Why - MarketBeat

Replimune Group (NASDAQ:REPL) Trading 11.1% Higher - Here's Why  MarketBeat

Replimune Group (NASDAQ:REPL) Trading 11.1% Higher - Here's Why - MarketBeat

Click here to get full coverage on Replimune Group (NASDAQ:REPL) Stock Price Down 8% - Here's What Happened - MarketBeat

Replimune Group (NASDAQ:REPL) Stock Price Down 8% - Here's What Happened  MarketBeat

Replimune Group (NASDAQ:REPL) Stock Price Down 8% - Here's What Happened - MarketBeat

Click here to get full coverage on $REPL stock is down 38% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is down 38% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is down 38% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on $REPL stock is up 10% today. Here's what we see in our data. - Quiver Quantitative

$REPL stock is up 10% today. Here's what we see in our data.  Quiver Quantitative

$REPL stock is up 10% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Erste Asset Management GmbH Increases Stock Position in Replimune Group, Inc. $REPL - MarketBeat

Erste Asset Management GmbH Increases Stock Position in Replimune Group, Inc. $REPL  MarketBeat

Erste Asset Management GmbH Increases Stock Position in Replimune Group, Inc. $REPL - MarketBeat

Click here to get full coverage on 44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025 - Stock Titan

44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025  Stock Titan

44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025 - Stock Titan

Click here to get full coverage on Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection - Quiver Quantitative

Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection  Quiver Quantitative

Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection - Quiver Quantitative

Click here to get full coverage on Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman - PR Newswire

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman  PR Newswire

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman - PR Newswire

Click here to get full coverage on Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Hold" by Analysts - MarketBeat

Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Hold" by Analysts  MarketBeat

Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Hold" by Analysts - MarketBeat

Click here to get full coverage on Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade) - Seeking Alpha

Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade)  Seeking Alpha

Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade) - Seeking Alpha

Click here to get full coverage on Replimune Group (REPL) director gifts 25,000 common shares - Stock Titan

Replimune Group (REPL) director gifts 25,000 common shares  Stock Titan

Replimune Group (REPL) director gifts 25,000 common shares - Stock Titan

Click here to get full coverage on Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism - simplywall.st

Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism  simplywall.st

Replimune Group (REPL): Valuation Update After FDA Acceptance of RP1 Application Spurs Investor Optimism - simplywall.st

Click here to get full coverage on Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market? - simplywall.st

Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market?  simplywall.st

Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market? - simplywall.st

Click here to get full coverage on REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman - PR Newswire

REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman  PR Newswire

REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman - PR Newswire

Click here to get full coverage on Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions? - Bitget

Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions?  Bitget

Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions? - Bitget

Click here to get full coverage on Replimune stock gains on FDA Type A meeting (REPL:NASDAQ) - Seeking Alpha

Replimune stock gains on FDA Type A meeting (REPL:NASDAQ)  Seeking Alpha

Replimune stock gains on FDA Type A meeting (REPL:NASDAQ) - Seeking Alpha

Click here to get full coverage on Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig - GuruFocus

Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig  GuruFocus

Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig - GuruFocus

Click here to get full coverage on Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st

Is Replimune Group (NASDAQ:REPL) A Risky Investment?  simplywall.st

Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st

Click here to get full coverage on Why Is Replimune Stock (REPL) Up 105% Today? - TipRanks

Why Is Replimune Stock (REPL) Up 105% Today?  TipRanks

Why Is Replimune Stock (REPL) Up 105% Today? - TipRanks

Click here to get full coverage on Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today - Benzinga

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today  Benzinga

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today - Benzinga

Click here to get full coverage on Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting - Stock Titan

Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting  Stock Titan

Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting - Stock Titan

Click here to get full coverage on FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection - Stock Titan

FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection  Stock Titan

FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection - Stock Titan

Click here to get full coverage on Replimune burns cash as April 10 RP1 FDA action date approaches - Stock Titan

Replimune burns cash as April 10 RP1 FDA action date approaches  Stock Titan

Replimune burns cash as April 10 RP1 FDA action date approaches - Stock Titan

Click here to get full coverage on REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is  GlobeNewswire

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire

Click here to get full coverage on Insider Sale: Chief Financial Officer of $REPL Sells 9,154 Shares - Quiver Quantitative

Insider Sale: Chief Financial Officer of $REPL Sells 9,154 Shares  Quiver Quantitative

Insider Sale: Chief Financial Officer of $REPL Sells 9,154 Shares - Quiver Quantitative

Click here to get full coverage on Replimune stock down after report on drug rejection (REPL) - Seeking Alpha

Replimune stock down after report on drug rejection (REPL)  Seeking Alpha

Replimune stock down after report on drug rejection (REPL) - Seeking Alpha

Click here to get full coverage on Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - TradingView

Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months  TradingView

Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - TradingView

Click here to get full coverage on REPL Stock Up 33% after 5-Day Win Streak - Trefis

REPL Stock Up 33% after 5-Day Win Streak  Trefis

REPL Stock Up 33% after 5-Day Win Streak - Trefis

Click here to get full coverage on REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman - PR Newswire

REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman  PR Newswire

REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman - PR Newswire

Click here to get full coverage on Replimune Group, Inc. Shares Promising Data on RP1 and Nivolumab Combination for Acral Melanoma at ESMO Congress 2025 | REPL Stock News - Quiver Quantitative

Replimune Group, Inc. Shares Promising Data on RP1 and Nivolumab Combination for Acral Melanoma at ESMO Congress 2025 | REPL Stock News  Quiver Quantitative

Replimune Group, Inc. Shares Promising Data on RP1 and Nivolumab Combination for Acral Melanoma at ESMO Congress 2025 | REPL Stock News - Quiver Quantitative

Click here to get full coverage on Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance - GuruFocus

Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance  GuruFocus

Replimune (REPL) Sees Shares Skyrocket Following FDA Acceptance - GuruFocus

Click here to get full coverage on Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ) - Seeking Alpha

Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ)  Seeking Alpha

Replimune stock falls as FDA rejects lead drug (REPL:NASDAQ) - Seeking Alpha

Click here to get full coverage on Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha

Replimune Group: The Prospects For FDA Approval After Rejection (REPL)  Seeking Alpha

Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha

Click here to get full coverage on REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm - Business Wire

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm  Business Wire

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm - Business Wire

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL - PR Newswire

Click here to get full coverage on Replimune Group, Inc. $REPL Shares Purchased by Readystate Asset Management LP - MarketBeat

Replimune Group, Inc. $REPL Shares Purchased by Readystate Asset Management LP  MarketBeat

Replimune Group, Inc. $REPL Shares Purchased by Readystate Asset Management LP - MarketBeat

Click here to get full coverage on Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more - Seeking Alpha

Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more  Seeking Alpha

Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more - Seeking Alpha

Click here to get full coverage on Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Johnson Fistel, PLLP Investigates Claims on Behalf of  GlobeNewswire

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Click here to get full coverage on REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire

REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT  GlobeNewswire

REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire

Click here to get full coverage on Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor Concerns - Hagens Berman - GlobeNewswire

Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor Concerns - Hagens Berman  GlobeNewswire

Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor Concerns - Hagens Berman - GlobeNewswire

Click here to get full coverage on REG - Jefferies Intl Ltd Intnl Personal Fin - Form8.5 EPT/NON-RI International Personal Fin Repl - TradingView

REG - Jefferies Intl Ltd Intnl Personal Fin - Form8.5 EPT/NON-RI International Personal Fin Repl  TradingView

REG - Jefferies Intl Ltd Intnl Personal Fin - Form8.5 EPT/NON-RI International Personal Fin Repl - TradingView

Click here to get full coverage on Noteworthy Monday Option Activity: UNH, REPL, CELC - Nasdaq

Noteworthy Monday Option Activity: UNH, REPL, CELC  Nasdaq

Noteworthy Monday Option Activity: UNH, REPL, CELC - Nasdaq

Click here to get full coverage on Why Replimune Stock Was Soaring Today - The Motley Fool

Why Replimune Stock Was Soaring Today  The Motley Fool

Why Replimune Stock Was Soaring Today - The Motley Fool

Click here to get full coverage on Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program (NASDAQ:REPL) - Seeking Alpha

Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program (NASDAQ:REPL)  Seeking Alpha

Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program (NASDAQ:REPL) - Seeking Alpha

Click here to get full coverage on REPL Stock Up 35% after 6-Day Win Streak - Trefis

REPL Stock Up 35% after 6-Day Win Streak  Trefis

REPL Stock Up 35% after 6-Day Win Streak - Trefis

Click here to get full coverage on Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire

Johnson Fistel, PLLP Begins Investigation on Behalf of  GlobeNewswire

Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire

Click here to get full coverage on Replimune Stock: Multiple Shots On Goal But A High Risk Binary Approaches (NASDAQ:REPL) - Seeking Alpha

Replimune Stock: Multiple Shots On Goal But A High Risk Binary Approaches (NASDAQ:REPL)  Seeking Alpha

Replimune Stock: Multiple Shots On Goal But A High Risk Binary Approaches (NASDAQ:REPL) - Seeking Alpha

Click here to get full coverage on Why Replimune Stock Plummeted by Almost 40% Today - The Motley Fool

Why Replimune Stock Plummeted by Almost 40% Today  The Motley Fool

Why Replimune Stock Plummeted by Almost 40% Today - The Motley Fool

Click here to get full coverage on Replimune (REPL) Stock Dips Amid FDA Meeting and Analyst Downgra - GuruFocus

Replimune (REPL) Stock Dips Amid FDA Meeting and Analyst Downgra  GuruFocus

Replimune (REPL) Stock Dips Amid FDA Meeting and Analyst Downgra - GuruFocus

Click here to get full coverage on Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL) - Seeking Alpha

Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL)  Seeking Alpha

REPL

Price Chart

Key Statistics

Technicals

About REPL

Latest News

Does Replimune Group (REPL) have the potential to rally 79.61% as Wall Street analysts expect? - MSN

Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire

Advanced Charts

Top Gainers

Top Losers